Evidence for Electroconvulsive Therapy (ECT) in Agitated Depression

Efficacy in Agitated Depression

ECT has demonstrated particular effectiveness in reducing severe mood symptoms and improving quality of life in patients with major depression, including those with agitation 1, 2, 3
A recent study found that patients who received ECT during hospitalization had a 50% lower risk of suicide in the first year after discharge compared to those who did not receive ECT 1, 2, 3
ECT shows greatest benefit for patients with psychotic features and those aged 45 years or older, characteristics often present in agitated depression 1, 2, 3

Most centers administer ECT three times weekly, though twice-weekly administration is common in other countries 4, 5
A typical course consists of 10-12 treatments, with initial improvement often observed after the first 5-6 treatments 4, 5
For agitated depression with severe symptoms, bilateral electrode placement may be preferred initially for more rapid response 4, 5

Medication management during ECT requires careful consideration, with certain medications like lithium, benzodiazepines, and carbamazepine to be discontinued prior to ECT due to risks of adverse effects 6
Olanzapine and mirtazapine can be continued during ECT as part of a maintenance treatment strategy 6

Patients with treatment-resistant depression showing agitation may particularly benefit from ECT, with evidence suggesting shorter hospital stays compared to those who refuse ECT 7
The presence of comorbid personality disorders does not contraindicate ECT use in agitated depression, though it may affect treatment response 8, 9
Neurological conditions are not absolute contraindications to ECT in agitated depression, though careful evaluation is needed 8, 9, 10

Patients requiring ECT typically have failed multiple medication trials, and while prior medication failure does reduce ECT efficacy somewhat, ECT remains highly effective even in medication-resistant patients, with a remission rate of 48% vs 65% without prior medication failure, according to the American Psychiatric Association 11, 12

The American College of Psychiatry recommends continuing vortioxetine during ECT unless specific side effects emerge, as it may provide ongoing antidepressant coverage and help prevent relapse after ECT completion 11, 12